Francesco Bonella

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1235219/publications.pdf

Version: 2024-02-01

163	5,427	76326	98798
papers	citations	40 h-index	67 g-index

185	185	185	5153
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia. Pneumologie, 2022, 76, 25-34.	0.1	0
2	Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology, 2022, 27, 66-75.	2.3	16
3	Communicating with patients with IPF: can we do it better?. ERJ Open Research, 2022, 8, 00422-2021.	2.6	2
4	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology, 2022, 27, 294-300.	2.3	15
5	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	5.6	15
6	Pulmonary sarcoidosis. , 2022, , 122-141.		1
7	Targeted therapy for pulmonary alveolar proteinosis: the time is now. European Respiratory Journal, 2022, 59, 2102971.	6.7	2
8	Defining anti-synthetase syndrome: a systematic literature review.. Clinical and Experimental Rheumatology, 2022, 40, 309-319.	0.8	1
9	Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Advances in Therapy, 2022, 39, 3392-3402.	2.9	12
10	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Annals of the Rheumatic Diseases, 2021, 80, 143-150.	0.9	120
11	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	2.6	22
12	Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting. European Respiratory Journal, 2021, 58, 2004188.	6.7	47
13	Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF. Orphanet Journal of Rare Diseases, 2021, 16, 111.	2.7	25
14	Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respiratory Research, 2021, 22, 125.	3.6	22
15	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	7.1	17
16	ERS clinical practice guidelines on treatment of sarcoidosis. European Respiratory Journal, 2021, 58, 2004079.	6.7	248
17	Unclassifiable, or simply unclassified interstitial lung disease?. Current Opinion in Pulmonary Medicine, 2021, 27, 405-413.	2.6	5
18	Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey. Frontiers in Medicine, 2021, 8, 711194.	2.6	8

#	Article	IF	Citations
19	Misconceptions regarding symptoms of sarcoidosis. Lancet Respiratory Medicine,the, 2021, 9, 816-818.	10.7	16
20	S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis. Respiration, 2021, 100, 238-271.	2.6	19
21	ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Research, 2020, 6, 00143-2020.	2.6	0
22	Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease. Respiration, 2020, 99, 628-636.	2.6	12
23	Hypersensitivity pneumonitis. Nature Reviews Disease Primers, 2020, 6, 65.	30.5	75
24	Looking into the future of sarcoidosis: what is next for treatment?. Current Opinion in Pulmonary Medicine, 2020, 26, 598-607.	2.6	10
25	Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment. Immunobiology, 2020, 225, 151997.	1.9	12
26	The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: is it of diagnostic value?. European Respiratory Journal, 2020, 56, 2001534.	6.7	10
27	Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine, 2020, 383, 1635-1644.	27.0	61
28	Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulmonary Medicine, 2020, 20, 128.	2.0	8
29	Serum KLâ€6 concentrations as a novel biomarker of severe COVIDâ€19. Journal of Medical Virology, 2020, 92, 2216-2220.	5.0	74
30	Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 797-808.	4.1	8
31	Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. Biomarkers in Medicine, 2020, 14, 665-674.	1.4	44
32	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.8	33
33	When the Game Changes. Chest, 2020, 158, 892-895.	0.8	36
34	Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. European Journal of Cancer, 2020, 131, 18-26.	2.8	50
35	Quantitative Lipidomics in Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 881-887.	5.6	25
36	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5.6	90

#	Article	IF	Citations
37	Pulmonary alveolar proteinosis. Nature Reviews Disease Primers, 2019, 5, 16.	30.5	244
38	Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia. Respiration, 2019, 98, 29-37.	2.6	5
39	The Burden of Sarcoidosis Symptoms from a Patient Perspective. Lung, 2019, 197, 155-161.	3.3	52
40	Research highlights from the 2018 ERS International Congress: interstitial lung diseases. ERJ Open Research, 2019, 5, 00215-2018.	2.6	5
41	THU0339â€...PULMONARY INVOLVEMENT AND OUTCOME IN SYSTEMIC SCLEROSIS (SSC) â€“ ILD-PH AS AN IMPORTANT SUBSET. , 2019, , .		0
42	Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSISÂtrials. European Respiratory Journal, 2019, 54, 1801797.	6.7	28
43	Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Research, 2019, 5, 00124-2019.	2.6	33
44	Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study. Journal of Clinical Medicine, 2019, 8, 2069.	2.4	8
45	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	2.4	118
46	Shaping the future of an ultra-rare disease. Current Opinion in Pulmonary Medicine, 2019, 25, 450-458.	2.6	14
47	Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients. Transplant Immunology, 2019, 52, 40-44.	1.2	5
48	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. Journal of Rheumatology, 2019, 46, 279-284.	2.0	36
49	Pulmonary Function Tests in Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 2019, , 85-95.	0.1	1
50	Late Breaking Abstract - The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey. , 2019, , .		1
51	Does anti-acid treatment influence disease progression in SSc-ILD ? data from the German SSc-network. , 2019, , .		1
52	Efficacy and safety of nintedanib in the elderly patient with IPF. , 2019, , .		1
53	Long term outcomes of immunomodulatory drugs in SSc-ILD - data from the German SSc-network. , 2019, , .		2
54	Potential clinical utility of MUC5B and TOLLIP single nucleotide polymorphisms (SNP) in in the management of patients with IPF. , 2019, , .		1

#	Article	IF	Citations
55	Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF). , 2019, , .		10
56	Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay. , 2019, , .		0
57	German Guideline for Idiopathic Pulmonary Fibrosis â€“ Update on Pharmacological Therapies 2017. Pneumologie, 2018, 72, 155-168.	0.1	47
58	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 317-326.	2.6	42
59	Phenotypes of organ involvement in sarcoidosis. European Respiratory Journal, 2018, 51, 1700991.	6.7	146
60	European Respiratory Society International Congress 2017: highlights from the Clinical Assembly. ERJ Open Research, 2018, 4, 00134-2017.	2.6	1
61	Serum YKLâ€40 in workers at an indiumâ€tin oxide production facility â€“ Reply. Respirology, 2018, 23, 342-342.	2.3	0
62	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	5.6	174
63	Patients with IPF and lung cancer: diagnosis and management. Lancet Respiratory Medicine,the, 2018, 6, 86-88.	10.7	67
64	Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies. Respiration, 2018, 96, 571-587.	2.6	21
65	Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Respiration, 2018, 96, 314-322.	2.6	41
66	The Management of Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2018, 5, 148.	2.6	42
67	Diagnosis and therapy of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) in Germany. , 2018, , .		2
68	Significance of pulmonary involvement in systemic sclerosis (SSc)â€“ data from the German SSc-network. , 2018, , .		2
69	Lung involvement and clinical characteristics in anti-MDA5 positive connective tissue diseases. , 2018, , .		1
70	Modified GAP stage as a predictor of acute exacerbation in idiopathic pulmonary fibrosis. , 2018, , .		0
71	Nailfold capillaroscopy findings in ILD patients: results from a single centre investigation.. , 2018, , .		0
72	Characterization of the gene network driving the whole lung lavage (WLL) outcome in Pulmonary Alveolar Proteinosis (PAP).. , 2018, , .		0

#	Article	IF	Citations
73	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.8	30
74	Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax, 2017, 72, 148-153.	5.6	66
75	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration, 2017, 93, 415-423.	2.6	63
76	Serum <scp>YKL</scp>â€40 is a reliable biomarker for pulmonary alveolar proteinosis. Respirology, 2017, 22, 1371-1378.	2.3	14
77	FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 123, 105-109.	2.9	25
78	Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. European Respiratory Journal, 2017, 49, 1501924.	6.7	38
79	Therapeutic targets in idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 131, 49-57.	2.9	92
80	Differential diagnosis of granulomatous lung disease: clues and pitfalls. European Respiratory Review, 2017, 26, 170012.	7.1	95
81	Idiopathic pleuroparenchymal fibroelastosis (PPFE) â€“ A case study of a rare entity. Revista Portuguesa De Pneumologia, 2017, 23, 352-355.	0.7	8
82	Coagulation factor XII regulates inflammatory responses in human lungs. Thrombosis and Haemostasis, 2017, 117, 1896-1907.	3.4	36
83	Unmet needs in the treatment of idiopathic pulmonary fibrosisâ€•insights from patient chart review in five European countries. BMC Pulmonary Medicine, 2017, 17, 124.	2.0	77
84	Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF). , 2017, , .		1
85	Extracorporeal membrane oxygenation for the treatment of acute exacerbation of interstitial lung diseases. , 2017, , .		0
86	A gene network to predict the clinical response to whole lung lavage (WLL), in pulmonary alveolar proteinosis (PAP). , 2017, , .		0
87	Diffusing capacity (DLCO) as a potential surrogate marker for scleroderma related lung diseaseâ€“data from the german network for systemic sclerosis. , 2017, , .		0
88	IL-9 and IL-9 receptor (IL-9r) expression in BALF lymphocytes in ILD patients: preliminary results. , 2017, , .		0
89	Serum anti DFS70 antibody titer and lung functional impairment in patients with interstitial lung disease (ILD). , 2017, , .		0
90	Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration, 2016, 92, 98-106.	2.6	52

#	Article	IF	Citations
91	A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis. Chest, 2016, 150, 251-253.	0.8	20
92	Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. Orphanet Journal of Rare Diseases, 2016, 11, 115.	2.7	100
93	An Important Step Forward, but Still a Way to Go. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 340-341.	5.6	5
94	How to handle IPF â€“ the new Portuguese consensus document. Revista Portuguesa De Pneumologia, 2016, 22, 70-72.	0.7	0
95	European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity. European Respiratory Journal, 2016, 48, 283-284.	6.7	8
96	Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1033-1034.	5.6	4
97	New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2016, 22, 434-441.	2.6	19
98	MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases, 2016, 11, 48.	2.7	22
99	European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. European Respiratory Journal, 2016, 47, 597-606.	6.7	101
100	Pulmonale Alveolarproteinose. , 2016, , 237-245.		0
101	LSC Abstract â€“ Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)?. , 2016, , .		0
102	Inhaled rhGM-CSF (molgramostim) in the first randomised, double-blind, placebo-controlled, international trial in patients with autoimmune alveolar proteinosis (aPAP). , 2016, , .		0
103	Detection of anti DFS70 antibodies in patients with interstitial lung disease (ILD) with and without connective tissue disease (CTD). , 2016, , .		0
104	Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP). , 2016, , .		0
105	Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures. , 2016, , .		1
106	Current and Future Therapies for Idiopathic Pulmonary Fibrosis. Pulmonary Therapy, 2015, 1, 1-18.	2.2	2
107	Pulmonary alveolar proteinosis in a cat. BMC Veterinary Research, 2015, 11, 302.	1.9	7
108	Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respiratory Research, 2015, 16, 116.	3.6	114

#	Article	IF	Citations
109	Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Design, Development and Therapy, 2015, 9, 6407.	4.3	37
110	Biomarker discovery in systemic sclerosis: state of the art. Current Biomarker Findings, 2015, , 47.	0.4	4
111	Update on therapeutic management of idiopathic pulmonary fibrosis. Therapeutics and Clinical Risk Management, 2015, 11, 359.	2.0	51
112	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. BioMed Research International, 2015, 2015, 1-10.	1.9	60
113	<scp>MUC</scp>5<scp>B</scp> promoter polymorphism in <scp>J</scp>apanese patients with idiopathic pulmonary fibrosis. Respirology, 2015, 20, 439-444.	2.3	95
114	Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis. Immunobiology, 2015, 220, 382-388.	1.9	4
115	Facts and promises on lung biomarkers in interstitial lung diseases. Expert Review of Respiratory Medicine, 2015, 9, 437-457.	2.5	19
116	Diagnosis of Sarcoidosis. Clinical Reviews in Allergy and Immunology, 2015, 49, 54-62.	6.5	86
117	GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. BMC Pulmonary Medicine, 2015, 15, 87.	2.0	63
118	New guideline on treatment of idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2015, 3, e31-e32.	10.7	4
119	Comparative analysis of multiple gene polymorphisms for acute exacerbation of idiopathic pulmonary fibrosis. , 2015, , .		2
120	Pulmonale Alveolarproteinose. , 2015, , 1-7.		0
121	Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD). , 2015, , .		0
122	Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD). , 2015, , .		0
123	Determination of a single nucleotide polymorphism (SNP) of the TNFalpha-R1 region (TNFRSF1A) in patients with lung sarcoidosis: Preliminary results. , 2015, , .		0
124	Different biopsy techniques for confirmation of sarcoidosis: The game for the best diagnostic yield is still open. , 2015, , .		0
125	Sporadic idiopathic non-specific interstitial pneumonia in monozygotic twin sisters. , 2015, , .		0
126	Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)?. , 2015, , .		0

#	Article	IF	Citations
127	Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 181-200.	2.1	54
128	Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?. European Respiratory Review, 2014, 23, 308-319.	7.1	99
129	Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPDgene polymorphisms. BMC Medical Genetics, 2014, 15, 4.	2.1	22
130	Alveolar and intraparenchymal proteasome in sarcoidosis. Respiratory Medicine, 2014, 108, 1534-1541.	2.9	7
131	Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respiratory Medicine, 2014, 108, 1031-1039.	2.9	163
132	Interstitial lung disease. European Respiratory Review, 2014, 23, 40-54.	7.1	182
133	Pulmonary alveolar proteinosis. Pneumologia, 2014, 63, 144, 147-55.	0.1	4
134	Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis. Orphanet Journal of Rare Diseases, 2013, 8, 53.	2.7	39
135	Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia. Immunobiology, 2013, 218, 930-937.	1.9	51
136	CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant inÂinterstitial lung diseases. Respiratory Medicine, 2013, 107, 1444-1452.	2.9	73
137	The Ambitious Goal of Validating Prognostic Biomarkers for Systemic Sclerosis-related Interstitial Lung Disease. Journal of Rheumatology, 2013, 40, 1034-1036.	2.0	5
138	Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis. European Respiratory Journal, 2012, 40, 1468-1474.	6.7	31
139	Whole-Lung Lavage: A Successful Treatment for Restoring Acinar Ventilation Distribution in Primary Acquired Pulmonary Alveolar Proteinosis. Respiration, 2012, 84, 70-74.	2.6	3
140	Chronic Hypersensitivity Pneumonitis. Clinics in Chest Medicine, 2012, 33, 151-163.	2.1	106
141	Self‐reported asthma and respiratory symptoms among Italian amateur athletes. European Journal of Sport Science, 2012, 12, 96-102.	2.7	0
142	Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases. Diagnostic Pathology, 2012, 7, 160.	2.0	27
143	KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome. Orphanet Journal of Rare Diseases, 2012, 7, 99.	2.7	5
144	Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respiratory Medicine, 2012, 106, 1756-1764.	2.9	54

#	Article	IF	Citations
145	Hypersensitivity Pneumonitis. Immunology and Allergy Clinics of North America, 2012, 32, 537-556.	1.9	26
146	Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 1374-1380.	0.6	24
147	Pulmonary alveolar proteinosis: New insights from a single-center cohort of 70 patients. Respiratory Medicine, 2011, 105, 1908-1916.	2.9	98
148	Serum KL-6 As Predictor Of Disease Progression In Patients With Pulmonary Alveolar Proteinosis. , 2011, , .		0
149	Serum Kl-6 Is A Useful Diagnostic And Prognostic Biomarker In Idiopathic Interstitial Pneumonia In German Patients. , 2011, , .		0
150	A Multicenter, International Evaluation Of Blood Testing For The Diagnosis Of Autoimmune Pulmonary Alveolar Proteinosis. , 2011, , .		1
151	Serum Levels Of KL-6, A Biomarker For Interstitial Lung Diseases, In Caucasian Patients With Idiopathic Interstitial Pneumonias. , 2010, , .		0
152	Serum Levels Of YKL-40, An Interstitial Lung Disease Biomarker, In Patients With Autoimmune Alveolar Proteinosis. , 2010, , .		0
153	Angiogenic and Angiostatic Chemokines in Idiopathic Pulmonary Fibrosis and Granulomatous Lung Disease. Respiration, 2010, 80, 372-378.	2.6	29
154	Diagnostic Modalities in Sarcoidosis: BAL, EBUS, and PET. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 404-408.	2.1	89
155	A female soccer player with recurrent haemoptysis and iron deficiency anaemia: idiopathic pulmonary haemosiderosis (IPH)--case report and literature review. BMJ Case Reports, 2010, 2010, bcr0620091969-bcr0620091969.	0.5	3
156	Significance of Bronchoalveolar Lavage for the Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1043-1047.	5.6	200
157	To BAL or Not to BAL: Is This a Problem in Diagnosing IPF?. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 380-380.	5.6	0
158	Acid reflux into the oesophagus does not influence exercise-induced airway narrowing in bronchial asthma. British Journal of Sports Medicine, 2008, 42, 545-549.	6.7	11
159	Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux. Scandinavian Journal of Gastroenterology, 2007, 42, 299-307.	1.5	14
160	Bronchoalveolar Lavage in Other Interstitial Lung Diseases. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 514-524.	2.1	98
161	Biomarkers. , 0, , 122-142.		1
162	ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Research, 0, , 00640-2021.	2.6	0

#	Article	IF	Citations
163	Genetic testing in interstitial lung disease: An international survey. Respirology, 0, , .	2.3	10